IDNA ETF Analysis: Genomics Immunology | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 335m USD | 12M Return: 70.6% | US46435U1925 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.44M
Warnings
No concerns identified
Tailwinds
Seasonality 7.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The iShares Genomics Immunology and Healthcare ETF (IDNA) is a passively managed fund that invests at least 80% of its assets in securities that mirror its underlying index, with the flexibility to allocate up to 20% to derivatives such as futures, options, and swap contracts, as well as cash equivalents. The index targets developed and emerging market companies positioned to benefit from long-term advancements in genomics, immunology, and bioengineering-subsectors of biotechnology focused on gene-based research, immune system therapies, and engineered biological systems. The fund is structured as non-diversified, meaning it may hold a more concentrated portfolio compared to diversified ETFs, which can result in greater exposure to individual securities within the healthcare innovation theme.
- FDA approves breakthrough gene therapies and immunotherapies
- Biotech M&A wave lifts genomics sector valuations
- Drug pricing regulation pressures constituent margins
As of November 11, 2026, the stock is trading at USD 42.53 with a total of 117,976 shares traded. Over the past week, the price has changed by +0.14%, over one month by +2.33%, over three months by +20.62% and over the past year by +70.61%.
Current recommended Stop Loss: 40.70 (which is 4.3% or 1.2 ATR below the current price).
Genomics Immunology has no consensus analysts rating.